drugset / Trial / NCT07000149
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a Phase Ib/III, randomized, multicenter, global study evaluating the efficacy and safety of volrustomig in combination with casdatifan for the first-line (1L) treatment of participants with advanced clear cell renal cell carcinoma (ccRCC).
Timeline
- Start
- 2025-07-28
- Primary completion
- 2030-02-21
- Completion
- 2032-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Casdatifan | Small molecule | — | Oral |
| Comparator | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Comparator | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |